Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Determining how to optimally use FDA-approved drugs in chronic GvHD

Iskra Pusic • 17 Feb 2023
Tandem Meetings 2023
General Belumosudil Ibrutinib Ruxolitinib

Iskra Pusic, MD, MSCI, Washington University School of Medicine, St. Louis, MO, emphasizes the need to conduct further studies to determine how to best use FDA-approved drugs for chronic graft-versus-host disease (GvHD), highlighting the possibility to combine several of these agents together. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Iskra Pusic

1:32
GvHD highlights: use of biomarkers to guide treatment
Iskra Pusic • 17 Feb 2023
5:47
Use of belimumab for prophylaxis of chronic GvHD
Iskra Pusic • 24 Apr 2022
1:53
Advances and unmet needs in chronic GvHD
Iskra Pusic • 24 Apr 2022
4:21
Recent advances in the management of acute GvHD
Iskra Pusic • 22 Sep 2021

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals